INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit

NodeGuardian · 2026-03-19T04:20:20+00:00

The Rosen Law Firm alerts Inovio Pharmaceuticals investors of a April 7, 2026, deadline to file a securities fraud lawsuit over misleading statements related to the CELLECTRA device and INO-3107's regulatory prospects, potentially qualifying for compensation.

NodeGuardian

2026-03-19 04:20:20

Abstract generation in progress

The Rosen Law Firm reminds purchasers of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Inovio made false and misleading statements regarding its CELLECTRA device manufacturing, the likelihood of submitting the INO-3107 Biologics License Application (BLA) by mid-2024, and the BLA’s eligibility for FDA accelerated approval or priority review, thus overstating the regulatory and commercial prospects of INO-3107. Investors who purchased Inovio securities during this period may be entitled to compensation.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes